+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Tumor Drugs Market by Drug Class, Molecule Type, Indication, Route Of Administration, Therapy Line, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030- Product Image
Anti-Tumor Drugs Market by Drug Class, Molecule Type, Indication, Route Of Administration, Therapy Line, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Anti-Tumor Drugs Market by Drug Class, Molecule Type, Indication, Route Of Administration, Therapy Line, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5367839
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anti-tumor drugs market is experiencing significant transformation as emerging therapies, global supply chain shifts, and evolving payment models redefine industry strategies. Senior executives navigating this landscape require precise, actionable insights to capture opportunity, manage risk, and set their organizations apart in a highly competitive environment.

Market Snapshot: Anti-Tumor Drugs Market

The anti-tumor drugs market grew from USD 39.14 billion in 2024 to USD 44.03 billion in 2025 and is projected to expand at a CAGR of 12.28%, reaching USD 78.44 billion by 2030. Rapid innovation, shifting regulatory frameworks, and changing reimbursement structures are influencing investment priorities and market dynamics, demanding agile responses from industry leaders.

Scope & Segmentation

This report provides a robust framework for understanding market dynamics and supporting strategic decisions. Segmentation covers brands, technologies, distribution, and regional trends relevant to drug development, regulatory approvals, and commercialization.

  • Drug Classes: Chemotherapy, Hormonal Therapy, Immunotherapy, Targeted Therapy
  • Molecule Types: Monoclonal Antibody, Nucleic Acid, Peptide, Small Molecule
  • Key Indications: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
  • Routes of Administration: Intravenous, Oral, Subcutaneous, Topical
  • Therapy Lines: Combination, First Line, Maintenance, Second Line
  • Distribution Channels: Hospital Pharmacy (Inpatient, Outpatient), Online Pharmacy, Retail Pharmacy
  • End Users: Ambulatory Surgical Centers, Clinics, Home Care, Hospitals (Private, Public)
  • Patient Age Groups: Adult, Geriatric, Pediatric
  • Geographies: Americas (including United States and major states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (countries covering UK, Germany, France, and others), Asia-Pacific (including China, India, Japan, Australia, and more)
  • Top Companies: F. Hoffmann-La Roche, Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, Johnson & Johnson, AstraZeneca, Amgen, Eli Lilly, AbbVie

Key Takeaways for Decision-Makers

  • Scientific innovation in molecular targeting and immuno-oncology is driving substantial shifts in standard-of-care protocols and influencing investment in R&D portfolios.
  • New technologies, including digital pathology and artificial intelligence, are accelerating drug discovery, facilitating quicker biomarker identification and patient stratification.
  • Strategic alliances, mergers, and partnerships between biotech innovators and established pharmaceutical companies are reshaping pipeline development and market entry strategies.
  • Combination regimens that pair immunotherapies with targeted agents are redefining efficacy standards and broadening treatment options.
  • Regional disparities in healthcare infrastructure, reimbursement frameworks, and manufacturing capabilities shape both market access and long-term growth prospects.
  • Understanding core segments such as therapy lines, routes of administration, and patient age groups enables precise tailoring of products and commercialization plans.

Tariff Impact and Supply Chain Pressures

Recent US tariffs on active pharmaceutical ingredients and biologic imports are elevating raw material costs and compelling manufacturers to rethink supply chains. Companies are responding by diversifying suppliers, relocating production, and entering long-term contracts to mitigate risk. This environment favors larger organizations with flexible capital and established supplier relationships. Tariff-driven cost increases are influencing payer negotiations and slowing the adoption of high-cost biologics, reinforcing the need for transparent pricing and robust financial forecasting.

Methodology & Data Sources

This report leverages a blend of primary interviews with industry experts and health economics professionals, combined with secondary research from peer-reviewed literature, regulatory documentation, proprietary datasets, and official healthcare statistics. Advanced modeling, data validation, and sensitivity analysis ensure accuracy and actionable results grounded in current market realities.

Why This Report Matters

  • Provides a structured, objective view of evolving anti-tumor drug markets and actionable levers for senior decision-makers.
  • Delivers in-depth segmentation and regional analysis for more effective product development, go-to-market planning, and risk mitigation.
  • Highlights the interplay of innovation, regulatory changes, and supply chain contingencies, equipping executives with insights to prioritize strategic responses.

Conclusion

Senior leaders in oncology pharmaceuticals will find clear pathways for growth, differentiation, and partnership in this report. Aligning R&D focus, operational agility, and regional strategy with market trends remains crucial for future success in anti-tumor drug development and commercialization.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-Tumor Drugs Market, by Drug Class
8.1. Introduction
8.2. Chemotherapy
8.3. Hormonal Therapy
8.4. Immunotherapy
8.5. Targeted Therapy
9. Anti-Tumor Drugs Market, by Molecule Type
9.1. Introduction
9.2. Monoclonal Antibody
9.3. Nucleic Acid
9.4. Peptide
9.5. Small Molecule
10. Anti-Tumor Drugs Market, by Indication
10.1. Introduction
10.2. Breast Cancer
10.3. Colorectal Cancer
10.4. Lung Cancer
10.5. Prostate Cancer
11. Anti-Tumor Drugs Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
11.5. Topical
12. Anti-Tumor Drugs Market, by Therapy Line
12.1. Introduction
12.2. Combination
12.3. First Line
12.4. Maintenance
12.5. Second Line
13. Anti-Tumor Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.2.1. Inpatient Pharmacy
13.2.2. Outpatient Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Anti-Tumor Drugs Market, by End User
14.1. Introduction
14.2. Ambulatory Surgical Centers
14.3. Clinics
14.4. Home Care
14.5. Hospitals
14.5.1. Private
14.5.2. Public
15. Anti-Tumor Drugs Market, by Patient Age Group
15.1. Introduction
15.2. Adult
15.3. Geriatric
15.4. Pediatric
16. Americas Anti-Tumor Drugs Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa Anti-Tumor Drugs Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific Anti-Tumor Drugs Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. F. Hoffmann-La Roche Ltd
19.3.2. Bristol-Myers Squibb Company
19.3.3. Merck & Co., Inc.
19.3.4. Pfizer Inc.
19.3.5. Novartis AG
19.3.6. Johnson & Johnson
19.3.7. AstraZeneca PLC
19.3.8. Amgen Inc.
19.3.9. Eli Lilly and Company
19.3.10. AbbVie Inc.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. ANTI-TUMOR DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTI-TUMOR DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTI-TUMOR DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 22. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTI-TUMOR DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY NUCLEIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 74. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 77. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 79. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 81. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 89. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 133. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 135. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 138. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 140. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 142. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 143. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 145. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 163. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 165. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 168. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 170. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 172. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 173. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 175. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 178. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 180. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 182. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 215. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 218. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 220. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 233. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 235. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 236. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 238. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 240. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 242. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 243. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 244. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 245. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 248. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 250. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 252. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 262. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 273. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 274. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 275. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 278. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 280. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 282. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 283. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 284. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 285. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 286. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 288. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 290. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 292. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 303. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 304. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 305. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 306. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 308. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 310. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 312. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 313. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 314. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 315. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 316. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 318. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 320. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 321. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 322. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 327. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 328. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 329. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 330. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 331. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 332. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 334. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 335. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 336. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 337. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 338. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 339. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 340. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 341. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 342. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 343. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 344. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 345. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 346. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 347. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 348. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 349. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 350. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MIL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Anti-Tumor Drugs market report include:
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • AstraZeneca PLC
  • Amgen Inc.
  • Eli Lilly and Company
  • AbbVie Inc.

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 44.03 Billion
Forecasted Market Value ( USD ) by 2030 $ 78.44 Billion
Compound Annual Growth Rate12.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antineoplastic Agents Market by Product Type, Route Of Administration, Indication, Distribution Channel - Global Forecast to 2030 - Product Image

Antineoplastic Agents Market by Product Type, Route Of Administration, Indication, Distribution Channel - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Anti-Neoplastic Agents Market Report 2025 - Product Image

Anti-Neoplastic Agents Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Cytotoxic Drugs - Global Strategic Business Report - Product Image

Cytotoxic Drugs - Global Strategic Business Report

  • Report
  • 462 Pages
  • Global
From
Taxane Antineoplastic Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Taxane Antineoplastic Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 115 Pages
  • Global
From
Antineoplastic Agents - Global Strategic Business Report - Product Image

Antineoplastic Agents - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From

About the Anticancer Agent Market

The Anticancer Agent market is a segment of the Healthcare Services industry that focuses on the development and distribution of drugs and treatments for cancer. These agents are designed to target and destroy cancer cells while minimizing the damage to healthy cells. They can be administered orally, intravenously, or topically, depending on the type of cancer and the patient's individual needs. Anticancer agents are used in combination with other treatments such as radiation and chemotherapy to provide the best possible outcome for the patient. The Anticancer Agent market is highly competitive, with many companies vying for market share. Companies in this market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.